SEC Form 4 · accession 0001661181-18-000041

Organogenesis Holdings Inc. · ORGO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Brian Grow

Officer — Chief Commercial Officer

Period of report

Dec 10, 2018

Accepted (ET)

Dec 12, 2018 · 8:30 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001661181

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Dec 10, 2018	A	1,462	—	A	1,462	D

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F3,F2	$1.70	Dec 10, 2018	A	667	A	—	Oct 2, 2019	Common Stock	667	667	D
Stock Option (Right to Buy)^F4,F2	$1.70	Dec 10, 2018	A	1,151	A	—	Apr 15, 2020	Common Stock	1,151	1,151	D
Stock Option (Right to Buy)^F5,F2	$1.44	Dec 10, 2018	A	958	A	—	Oct 17, 2021	Common Stock	958	958	D
Stock Option (Right to Buy)^F6,F2	$1.46	Dec 10, 2018	A	805	A	—	Aug 21, 2022	Common Stock	805	805	D
Stock Option (Right to Buy)^F7,F2	$4.49	Dec 10, 2018	A	805	A	—	Jul 17, 2023	Common Stock	805	805	D
Stock Option (Right to Buy)^F8,F2	$1.24	Dec 10, 2018	A	958	A	—	Jan 12, 2025	Common Stock	958	958	D
Stock Option (Right to Buy)^F10,F9	$2.47	Dec 10, 2018	A	4,060	A	—	Aug 11, 2025	Common Stock	4,060	4,060	D
Stock Option (Right to Buy)^F12,F11	$1.18	Dec 10, 2018	A	30,450	A	—	Apr 10, 2024	Common Stock	30,450	30,450	D
Stock Option (Right to Buy)^F14,F13	$3.46	Dec 10, 2018	A	102,200	A	—	May 4, 2027	Common Stock	102,200	102,200	D
Stock Option (Right to Buy)^F16,F15	$3.46	Dec 10, 2018	A	60,900	A	—	May 4, 2027	Common Stock	60,900	60,900	D

Explanation of responses

F1Received in connection with the Issuer's business combination (the "Merger") with Organogenesis Inc. ("Organogenesis") in accordance with the terms of the Agreement and Plan of Merger dated as of August 17, 2018 among the Issuer, which was then referred to as Avista Healthcare Public Acquisition Corp., Avista Healthcare Merger Sub, Inc. and Organogenesis, in exchange for 720 shares of common stock of Organogenesis.
F10Received in connection with the Merger in exchange for an option to acquire 2,000 shares of common stock of Organogenesis for $5.00 per share.
F11The shares underlying the option vested or shall vest 20% annually beginning on April 1, 2015.
F12Received in connection with the Merger in exchange for an option to acquire 15,000 shares of common stock of Organogenesis for $2.38 per share.
F13The shares underlying the option vested or shall vest 20% annually beginning on December 31, 2017.
F14Received in connection with the Merger in exchange for an option to acquire 50,345 shares of common stock of Organogenesis for $7.01 per share.
F15The shares underlying the option vested or shall vest 20% annually beginning on January 1, 2018.
F16Received in connection with the Merger in exchange for an option to acquire 30,000 shares of common stock of Organogenesis for $7.01 per share.
F2100% of the shares subject to this option are fully vested and exercisable.
F3Received in connection with the Merger in exchange for an option to acquire 329 shares of common stock of Organogenesis for $3.45 per share.
F4Received in connection with the Merger in exchange for an option to acquire 567 shares of common stock of Organogenesis for $3.45 per share.
F5Received in connection with the Merger in exchange for an option to acquire 472 shares of common stock of Organogenesis for $2.92 per share.
F6Received in connection with the Merger in exchange for an option to acquire 397 shares of common stock of Organogenesis for $2.95 per share.
F7Received in connection with the Merger in exchange for an option to acquire 397 shares of common stock of Organogenesis for $9.10 per share.
F8Received in connection with the Merger in exchange for an option to acquire 472 shares of common stock of Organogenesis for $2.50 per share.
F9The shares underlying the option vested or shall vest 25% annually beginning on August 11, 2016.